Core Insights - Earth Science Tech, Inc. (ETST) has qualified for and been listed on the newly launched OTCID tier of the OTC Markets, reflecting its commitment to enhanced disclosure and compliance standards [1][2] - The CEO, Giorgio R. Saumat, highlighted the company's significant turnaround over the past two years and expressed optimism about future growth and increased investor confidence due to this new designation [3] Company Overview - ETST operates as a strategic holding company focused on acquiring and optimizing high-potential businesses, with current operations in compounding pharmaceuticals, telemedicine, and real estate development through various subsidiaries [4] - The company's subsidiaries include RxCompoundStore.com, Peaks Curative, Avenvi, Mister Meds, and others, each specializing in different aspects of healthcare and real estate [4][10] Subsidiary Highlights - **RxCompoundStore.com**: A fully licensed compounding pharmacy serving multiple states and actively pursuing licensure in remaining U.S. states [5] - **Mister Meds**: A compounding pharmacy in Texas that received full licensure in March 2025 and is expanding its service area [6] - **Peaks Curative**: A telemedicine platform offering consultations for compounded medications and recently expanded into the veterinary market [7] - **Las Villas Health Care**: A healthcare facility focused on the Spanish-speaking community, providing specialized health services [8] - **Avenvi**: A diversified real estate company managing development and financing activities, overseeing a $5 million share repurchase program [10] - **Earth Science Foundation**: A nonprofit organization supporting individuals with financial needs for prescription costs [11]

Miami, FL, June 26, 2025 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or “Company”), a strategic holding company, focused on value creation through the acquisition, operational optimization, and management of its operating businesses, today shares its financial results for the year ended March 31, 2025. For the fiscal year ended March 31, 2025, the Company reported the following results: Cash: $1,473,228, compared to $697,721 as of March 31, 2024—an increase of $775,507, representing a 1 ...

Hims & Hers Health shares rocketed higher over the last year, rewarding investors.When it comes to healthcare stocks, many investors pay attention to the usual suspects: Eli Lilly, Novo Nordisk, CVS Health, or Johnson & Johnson. These companies have built up enormous brand equity thanks to blockbuster drugs and widely recognized pharmacy management services.With the exception of CVS, whose shares have risen 46% so far this year, none of the other companies have generated robust stock price returns so far in ...

Core Insights - Teladoc Health, Inc. is actively participating in the Goldman Sachs 46th Annual Global Healthcare Conference, indicating its commitment to engaging with investors and stakeholders in the healthcare sector [1]. Group 1: Company Overview - The CEO, Charles Divita, recently celebrated his one-year anniversary in the role, expressing excitement about the potential of virtual care to address healthcare challenges [4]. - Divita highlighted the positive aspects of the company, including its assets, talent level, and market position, which exceeded his expectations upon joining [4]. - The CEO also acknowledged the need for changes and the identification of opportunities and challenges that the company must address moving forward [4].

Core Insights - LifeMD, Inc. is a leading provider of virtual primary care services, offering telemedicine and access to various healthcare services across more than 200 conditions [1][2] - The company will participate in two investor conferences in June, focusing on topics related to consumer and enterprise healthcare solutions [2] Company Overview - LifeMD provides a vertically integrated digital care platform, a 50-state affiliated medical group, and a 22,500-square-foot affiliated pharmacy [1] - The services offered include primary care, men's and women's health, weight management, and hormone therapy [1] Upcoming Events - Management will participate in the BTIG Obesity Health Forum on June 18, discussing "Direct to Consumer vs. Direct to Enterprise" [2] - The company will also be present at the Truist Securities Healthcare Disruptors & Digital Health Conference on June 24-25, with a panel discussion on "Tailored Approach to Weight Loss Solutions" [2]

Company Overview - Hims & Hers Health is a telemedicine platform providing access to various medications, including those for skin care, anxiety, sexual health, and weight loss [4] - The company operates on a subscription model, boasting 2.4 million subscribers at the end of Q1, representing a 38% year-over-year increase [5] - Revenue for the quarter reached $586 million, reflecting a remarkable 111% year-over-year growth [5] Business Model and Strategy - The subscription revenue model allows for high gross margins and recurring income [6] - By maintaining a primarily online business, Hims & Hers can reduce marketing expenses and invest in technology and research and development [6] - The company is focusing on AI investments to better understand customer data and unlock new expansion opportunities [7] Market Performance and Analyst Sentiment - Hims & Hers shares have increased by 157% over the past year, outperforming the market [2] - Despite the company's growth, Wall Street analysts have maintained neutral to bearish ratings, with no compelling buy ratings from major banks [10] - The average price estimate among analysts is approximately $48, indicating a potential 12% downside from current trading levels [10] Short Interest and Volatility - Approximately 35% of Hims & Hers' float is sold short, which is significantly higher than the typical benchmark of 10% [13] - High short interest can lead to increased volatility and potential short squeezes, contributing to stock price fluctuations [14] - The stock's volatility raises concerns about its suitability as a long-term investment [15] Investment Outlook - Hims & Hers represents a compelling opportunity at the intersection of healthcare and technology, with strong user acquisition and monetization capabilities [16] - The potential of AI in healthcare supports the company's long-term growth vision [17] - However, the stock's behavior resembles that of a meme stock, suggesting it may be more suitable for swing trading rather than a solid long-term investment [18][19]

Core Insights - The event hosted by GeeVida Health and Life Time focuses on longevity science and holistic health, featuring industry leaders sharing strategies for healthy living and aging [1][2] - GeeVida Health is a concierge telemedicine platform that emphasizes personalized care and health optimization, offering services for various health conditions [3] - Life Time operates a network of athletic country clubs and wellness programs, promoting healthy living and aging through a comprehensive ecosystem [4][5] Group 1: Event Details - The event will take place on June 14, 2025, at the UC Irvine Beall Applied Innovation Center, running from 9:00 a.m. to 5:30 p.m. [1] - Attendees will have networking opportunities with industry specialists and access to exhibitors showcasing performance and longevity innovations [2] Group 2: Key Speakers and Topics - Dr. Kambiz Farbakhsh will discuss the science behind aging well and future human performance [4] - Bahram Akradi will share insights on breakthroughs in longevity [4] - James LaValle will present a blueprint for lifelong health [4] - Other speakers include experts on the mind-body connection, nutritional strategies, and holistic wellness approaches [4] Group 3: Company Profiles - GeeVida Health provides state-of-the-art telemedicine services focused on health optimization and chronic disease management, ensuring personalized care [3] - Life Time operates 180 athletic country clubs and offers a range of wellness programs, recently recognized as a Great Place to Work® [5]

Financial Data and Key Metrics Changes - The meeting confirmed that a majority of the voting power of Teladoc Health's outstanding capital stock was present, indicating strong shareholder engagement [4][11] - Proposals regarding the election of directors and executive compensation were approved, reflecting shareholder confidence in management [11] Business Line Data and Key Metrics Changes - Specific financial data and performance metrics for individual business lines were not disclosed during the meeting [10] Market Data and Key Metrics Changes - No specific market data or key metrics were discussed in the meeting [10] Company Strategy and Development Direction and Industry Competition - The meeting focused on the election of directors and approval of executive compensation, suggesting a stable governance structure [11] - The approval of the incentive award plan indicates a commitment to aligning executive performance with shareholder interests [8] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during the meeting [10] Other Important Information - The meeting was conducted virtually, allowing stockholders to participate and vote online [5][9] - The results of the votes will be reported in a Form 8-K within four business days, ensuring transparency [11] Q&A Session Summary - No questions were raised during the Q&A session, indicating either satisfaction with the proposals or a lack of immediate concerns from shareholders [10]

Core Insights - LifeMD, Inc. has launched a limited-time introductory bundle for new self-pay patients, offering Wegovy at a discounted price of $199 along with access to its virtual weight management program for a total first-month cost of $299 [1][2] - The collaboration with Novo Nordisk enhances LifeMD's ability to provide branded GLP-1 medications through a fully integrated care experience, catering to the increasing number of self-pay patients seeking FDA-approved treatments [2][4] - The program will cost $599 per month starting from the second month, with no long-term commitment required [3] Company Overview - LifeMD is a leading provider of virtual primary care services, offering telemedicine, laboratory, and pharmacy services across more than 200 conditions, including weight management [6] - The company utilizes a vertically integrated platform, which includes a 50-state medical group and national diagnostic lab partnerships, to ensure a seamless experience from consultation to ongoing support [4][6] Product Offering - Wegovy is the first GLP-1 therapy approved in the U.S. for chronic weight management and cardiovascular risk reduction in adults with obesity, available in an injector pen by prescription for eligible LifeMD patients [5]

JPMorgan analyst Lisa C. Gill maintained a Neutral rating on Teladoc Health, Inc TDOC on Thursday with a price target of $9, down from the prior $11.On April 30, Teladoc reported first-quarter revenue of $629.4 million, down 3%, beating the consensus estimate of $619.29 million. The company reported a first-quarter loss of 53 cents per share, missing analyst estimates for a loss of 34 cents per share.Also Read: Teladoc Health Partners With Eli Liily’s LillyDirect to Expand Access to Zepbound For Weight Loss ...